Brief: Kezar Life Sciences Says Preliminarily Estimates Its Cash, Cash Equivalents & Marketable Securities As Of Dec 31, 2021 Were About $208.4 Million
Jan 7 (Reuters) - Kezar Life Sciences Inc KZR.O :
* KEZAR LIFE SCIENCES - PRELIMINARILY ESTIMATES ITS CASH,
CASH
EQUIVALENTS & MARKETABLE SECURITIES AS OF DEC 31, 2021 WERE
ABOUT $208.4 MILLION
Source text for Eikon: ID:
Further company coverage: KZR.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Kezar Life Sciences
See all newsNASDAQ TRADE HALT REASON NOT AVAILABLE AT 03:58 AM
NASDAQ TRADE HALT TRADING HALTED; FOR INFORMATION REQUESTED BY NASDAQ AT 03:28 AM
NASDAQ TRADE HALT TRADING HALTED; FOR INFORMATION REQUESTED BY NASDAQ AT 03:28 AM
NASDAQ TRADE HALT TRADING HALTED; FOR INFORMATION REQUESTED BY NASDAQ AT 07:50 PM
U.S. STOCKS ON THE MOVE-Sysco, Crowdstrike, GM